The IPO’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026, have drawn strong criticism for misquoting statutory provisions and introducing legally unsound interpretations. Stakeholders urge comprehensive revision before finalization.
Criticism Mounts Over IPO’s Draft Pharma Patent Guidelines (2026)
The Intellectual Property Office (IPO) released the Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026 fifteen days ago, sparking immediate backlash from legal and industry experts. The draft, intended to streamline pharmaceutical patent examination, contains multiple misquotations of the Patents Act, 1970, and introduces interpretations inconsistent with judicial precedent.
Critics highlight erroneous references to Sections 3(d) and 25, as well as an overly restrictive approach to 'enhanced efficacy' and salt forms. The guidelines appear to impose a higher evidentiary burden than required by law, potentially undermining legitimate innovation. Additionally, the draft fails to align with the Supreme Court’s clarifications in Novartis and subsequent judgments on Section 3(d).
The 2026 Draft Guidelines risk creating uncertainty and inconsistency in examination practice if adopted in current form.
Legal commentators are calling for a complete reworking of the document, emphasizing that examination guidelines must reflect statutory language and binding case law. Until revised, practitioners should continue to rely on existing guidelines and judicial pronouncements when prosecuting pharmaceutical patents.
Citations
- Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026
